Actinium Pharmaceuticals Stock Price, News & Analysis (NYSEAMERICAN:ATNM)

$0.67 0.03 (4.69 %)
(As of 11/20/2017 04:00 PM ET)
Previous Close$0.64
Today's Range$0.64 - $0.68
52-Week Range$0.54 - $1.72
Volume676,965 shs
Average Volume716,392 shs
Market Capitalization$52.02 million
P/E RatioN/A
Dividend YieldN/A

About Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals logoActinium Pharmaceuticals, Inc. (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company's products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131). Actimab-A is in human clinical trials stage for acute myeloid leukemia (AML) and Iomab-B in clinical trial stage for use in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. Its products under development are monoclonal antibodies labeled with radioisotopes. It has four product candidates in clinical trials: Actimab-A (HuM195-Ac-225), Iomab-B (BC8-I-131), BC8-Y-90 and BC8-SA. It is pursuing development of Actimab-A and Iomab-B, while BC8-Y-90 and BC8-SA are in physician sponsored clinical phase I trials.

Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: N/A
  • Previous Symbol: AMEX:ATNM
  • CUSIP: N/A
  • Web:
  • Trailing EPS: ($0.47)
  • Return on Equity: -260.21%
  • Return on Assets: -181.24%
  • Outstanding Shares: 80,030,000

Frequently Asked Questions for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

What is Actinium Pharmaceuticals' stock symbol?

Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) released its quarterly earnings data on Monday, March, 16th. The biotechnology company reported ($0.17) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.19) by $0.02. View Actinium Pharmaceuticals' Earnings History.

Where is Actinium Pharmaceuticals' stock going? Where will Actinium Pharmaceuticals' stock price be in 2017?

3 analysts have issued twelve-month price objectives for Actinium Pharmaceuticals' shares. Their predictions range from $3.00 to $6.00. On average, they expect Actinium Pharmaceuticals' share price to reach $5.00 in the next twelve months. View Analyst Ratings for Actinium Pharmaceuticals.

Are investors shorting Actinium Pharmaceuticals?

Actinium Pharmaceuticals saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 1,904,751 shares, an increase of 73.4% from the October 13th total of 1,098,379 shares. Based on an average trading volume of 1,484,562 shares, the days-to-cover ratio is currently 1.3 days. Currently, 2.5% of the company's shares are sold short.

Who are some of Actinium Pharmaceuticals' key competitors?

Who are Actinium Pharmaceuticals' key executives?

Actinium Pharmaceuticals' management team includes the folowing people:

  • Sandesh Seth, Executive Chairman of the Board, Chief Executive Officer (Age 53)
  • Steve O'Loughlin, Principal Financial and Accounting Officer
  • Nitya G. Ray Ph.D., Executive Vice President, Head - Product Development, Manufacturing and Supply Chain (Age 63)
  • Steven Price, Vice President - Clinical and Commercial Strategy
  • Mark Stanley Berger, Chief Medical Officer
  • C. David Nicholson Ph.D., Independent Director (Age 62)
  • Ajit S. Shetty Ph.D., Independent Director
  • Richard I. Steinhart CPA, Independent Director (Age 59)

How do I buy Actinium Pharmaceuticals stock?

Shares of Actinium Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Actinium Pharmaceuticals' stock price today?

One share of Actinium Pharmaceuticals stock can currently be purchased for approximately $0.67.

How big of a company is Actinium Pharmaceuticals?

Actinium Pharmaceuticals has a market capitalization of $52.02 million.

How can I contact Actinium Pharmaceuticals?

Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company can be reached via phone at +1-646-6773875.

MarketBeat Community Rating for Actinium Pharmaceuticals (NYSEAMERICAN ATNM)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  108 (Vote Outperform)
Underperform Votes:  39 (Vote Underperform)
Total Votes:  147
MarketBeat's community ratings are surveys of what our community members think about Actinium Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.00

Consensus Price Target History for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Price Target History for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Analysts' Ratings History for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

DateFirmActionRatingPrice TargetDetails
11/14/2017Maxim GroupSet Price TargetBuy$3.00View Rating Details
10/23/2017HC WainwrightReiterated RatingBuy$6.00View Rating Details
10/23/2017Roth CapitalReiterated RatingBuy$6.00View Rating Details
11/2/2016FBR & CoReiterated RatingBuy$9.00View Rating Details
(Data available from 11/20/2015 forward)


Earnings History and Estimates Chart for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Earnings by Quarter for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Earnings History by Quarter for Actinium Pharmaceuticals (NYSEAMERICAN ATNM)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/16/2015Q4 2014($0.19)($0.17)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

No earnings estimates for this company have been tracked by


Dividend History for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Actinium Pharmaceuticals (NYSEAMERICAN ATNM)

Insider Trades by Quarter for Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Insider Trades by Quarter for Actinium Pharmaceuticals (NYSEAMERICAN ATNM)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/2/2017Nitya G RayInsiderBuy10,000$0.75$7,500.00View SEC Filing  
8/2/2017Sandesh SethCEOBuy33,333$0.75$24,999.75View SEC Filing  
6/15/2017Sandesh SethChairmanBuy7,500$1.16$8,700.00View SEC Filing  
6/15/2017Steve O'loughlinInsiderBuy3,500$1.17$4,095.00View SEC Filing  
12/30/2016Sandesh SethInsiderBuy5,000$0.88$4,400.00View SEC Filing  
12/12/2016Sandesh SethInsiderBuy5,000$0.98$4,900.00View SEC Filing  
8/31/2016Sloan-Kettering Cance MemorialMajor ShareholderSell192,927$1.83$353,056.41View SEC Filing  
8/29/2016Sloan-Kettering Cance MemorialMajor ShareholderSell50,000$1.71$85,500.00View SEC Filing  
8/16/2016Sloan-Kettering Cance MemorialMajor ShareholderSell9,468$1.72$16,284.96View SEC Filing  
7/12/2016Sloan-Kettering Cance MemorialMajor ShareholderSell3,100$1.80$5,580.00View SEC Filing  
7/11/2016Sloan-Kettering Cance MemorialMajor ShareholderSell21,990$1.80$39,582.00View SEC Filing  
7/6/2016Sloan-Kettering Cance MemorialMajor ShareholderSell20,840$1.81$37,720.40View SEC Filing  
7/1/2016Sloan-Kettering Cance MemorialMajor ShareholderSell148,100$1.81$268,061.00View SEC Filing  
6/15/2016Sloan-Kettering Cance MemorialMajor ShareholderSell33,619$1.90$63,876.10View SEC Filing  
6/2/2016Sloan-Kettering Cance MemorialMajor ShareholderSell17,790$2.01$35,757.90View SEC Filing  
6/1/2016Sloan-Kettering Cance MemorialMajor ShareholderSell169,450$1.97$333,816.50View SEC Filing  
5/26/2016Sloan-Kettering Cance MemorialMajor ShareholderSell40,068$1.92$76,930.56View SEC Filing  
5/25/2016Sloan-Kettering Cance MemorialMajor ShareholderSell36,400$1.90$69,160.00View SEC Filing  
4/26/2016Sloan-Kettering Cance MemorialMajor ShareholderSell52,577$2.04$107,257.08View SEC Filing  
4/21/2016Sloan-Kettering Cance MemorialMajor ShareholderSell196,497$2.03$398,888.91View SEC Filing  
4/18/2016Sandesh SethChairmanBuy15,000$1.99$29,850.00View SEC Filing  
4/15/2016Sergio TraversaDirectorBuy3,000$2.02$6,060.00View SEC Filing  
4/14/2016Kaushik J DaveCEOBuy10,000$2.02$20,200.00View SEC Filing  
4/14/2016Richard I SteinhartDirectorBuy2,500$2.01$5,025.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Actinium Pharmaceuticals (NYSEAMERICAN ATNM)

Actinium Pharmaceuticals Inc (ATNM) Given a $3.00 Price Target by Maxim Group AnalystsActinium Pharmaceuticals Inc (ATNM) Given a $3.00 Price Target by Maxim Group Analysts - November 19 at 9:36 PM

Social Media

Social activity is not available for this stock.



Actinium Pharmaceuticals (NYSEAMERICAN ATNM) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.